SUPN - Supernus up 10% following 2021 earnings guidance boost Q3 beat

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) are up ~10% in after-hours trading after the company boosted its full-year earnings guidance and beat Q3 earnings estimates. Operating earnings for 2021 are now expected to be $90M-$95M, up from prior guidance of $70M-$90M. Net product sales in the quarter of $145.5M, a 4% decrease from the prior-year period, was primarily the result of decreased sales of Apokyn and Trokendi XR. Supernus emphasized the growth of Qelbree, its non-stimulant attention deficit/hyperactivity disorder ("ADHD") medicine that was approved in April. Monthly prescriptions reached 7,132 in September, an 37% increase from August. Also, the prescriber base has increased by 340% in Q3 compared to Q2 as more than 3,470 physicians prescribed the drug. An sNDA for Qelbree for adult ADHD is before the FDA with an April 29, 2022 action date. In the pipeline, Supernus expects to resubmit an NDA for SPN-830 (apomorphine infusion pump) for "on-off" episodes in Parkinson's

For further details see:

Supernus up 10% following 2021 earnings guidance boost, Q3 beat